What biotech or healthcare startup can an MPH or epidemiologist build without a wet lab?

Chronic rare hematologic cancers like myeloproliferative neoplasms (PV, ET, and JAK2+ myelofibrosis) suffer from fragmented longitudinal tracking across community oncology clinics. Public health and RWE founders can build EHR-integrated ruxolitinib-failure surveillance, red-blood-cell transfusion & MPN-SAF symptom registries, and precision salvage-trial recruitment platforms monetized by orphan biopharma sponsors.

Why is defining ruxolitinib failure a major public health and clinical trial bottleneck in myelofibrosis?

Outside specialized academic MPN centers, community practices lack uniform operational criteria for sub-optimal JAK inhibitor response or loss of response—especially when dose reductions are forced by anemia or thrombocytopenia. Delayed recognition shrinks the window for second-line switching (momelotinib, pacritinib, fedratinib), salvage clinical trials, or timely stem-cell transplant referral.

Spoke 02 // Epidemiology, HEOR & Care-Delivery Innovation

Where Can Public Health, RWE & Clinical Data Builders Create Immediate Impact in Rare Oncology?

59-Word Executive Answer

Chronic myeloproliferative neoplasms (MPNs) and JAK2+ myelofibrosis represent an overlooked sweet spot for zero-wet-lab public health and Real-World Evidence (RWE) startups. Because patients live for years in community clinics with unstandardized ruxolitinib-failure criteria, severe anemia/transfusion burdens, and uncaptured symptom drift, longitudinal RWE registries directly unlock salvage survival and lucrative orphan trial recruitment.

Section 01 // Epidemiological Bottleneck Analysis

Why Do Community Myelofibrosis Patients Fall Through Clinical Data Cracks?

Approximately 75% of US myelofibrosis cases present de novo (Primary MF), while ~25% evolve over years from antecedent Polycythemia Vera (PV) or Essential Thrombocythemia (ET). Median onset occurs at ages 60–70, meaning the majority of patients are managed outside elite academic MPN centers—often in busy community hematology-oncology clinics juggling solid tumors alongside rare blood cancers.

Three systemic public-health and clinical-operations failures compound mortality here:

Silent Dose-Reduction Attrition ("Pseudo-Stability"): When frontline ruxolitinib lowers hemoglobin or platelets, clinicians routinely titrate doses down (e.g., to <10 mg BID). Spleen enlargement and inflammatory cytokines quietly rebound, yet EHR structured fields rarely flag formal ruxolitinib failure until crisis—after which median survival is ~12–14 months.
Disconnect Between Patient-Reported Symptoms (MPN-SAF TSS) and Molecular Clones: Regulatory trials hinge on the MPN Symptom Assessment Form Total Symptom Score (TSS50: night sweats, bone pain, pruritus, early satiety, fatigue), yet routine clinic visits rarely capture longitudinal digital MPN-SAF alongside serial CBCs, RBC transfusion units, and JAK2 V617F / ASXL1 NGS panels.
Allogeneic Transplant & Salvage Trial Referral Lag: Allogeneic HSCT remains the only curative intervention, and second-line/combination trials have narrow platelet, hemoglobin, and blast-percentage eligibility windows. Late referral routinely disqualifies patients who were eligible six months earlier.

Section 02 // Three Build-Ready Public Health & RWE Startup Blueprints

What Specific Products Can MPH, Clinical Informatics & HEOR Teams Build?

Startup Wedge	Core Data Inputs (FHIR / Patient)	Clinical Impact	B2B Revenue & Buyer
1. Automated Ruxolitinib-Failure & Cytopenia Radar	Serial CBC trends (Hgb <10 g/dL, Plt <50–100 × 10⁹/L), pharmacy refill dose drops, spleen imaging NLP, PRBC transfusion CPT codes.	Flags community patients crossing RR6 (Response to Ruxolitinib after 6 Months) risk thresholds 6–12 months before overt progression.	Pharma Medical Affairs / HEOR & Specialty Pharmacy clinical decision support contracts.
2. Longitudinal MPN-SAF + VAF Patient Registry ("Direct-to-Patient RWE")	Patient-consented FHIR portal sync + weekly 90-second mobile MPN-SAF TSS check-in + NGS report OCR (`JAK2` VAF, CALR, ASXL1, EZH2).	Creates regulatory-grade external control arms and identifies exact trial-eligible cohorts (e.g., JAKi-exposed anemic vs. thrombocytopenic subsets).	Orphan trial site-less screening & recruitment contracts + regulatory RWE dataset licensing.
3. Transfusion-Burden & Iron-Overload Care Navigation	RBC transfusion cadence, serum ferritin / hepcidin proxies, erythropoiesis-stimulating agent (ESA) & ACVR1 inhibitor response logs.	Reduces avoidable ER/infusion-center utilization and optimizes timing of anemia-targeted therapies (e.g., momelotinib / luspatercept combos).	Value-based oncology care networks (Enhancing Oncology Model / Medicare Advantage specialty plans).

Section 03 // Technical & Regulatory Execution Path

How Can a Small Team Launch Within 90 Days Under 21st Century Cures Interoperability?

Patient-Mediated FHIR API Access: Under ONC 21st Century Cures Act rules, US patients have a statutory right to pull longitudinal labs (CBCs, LDH, ferritin), medication orders, and pathology notes via patient-facing SMART-on-FHIR endpoints across Epic, Cerner/Oracle, and community oncology portals—bypassing 18-month hospital IT sales cycles on Day 1.
Validated Open Clinical Instruments: Incorporate established prognostic models directly as transparent reference calculators (DIPSS, MIPSS70+ v2.0 incorporating ASXL1/EZH2/SRSF2/IDH1-2/U2AF1 high-molecular-risk mutations, and the RR6 model for early ruxolitinib survival stratification) as non-device clinical literature support tools under FDA CDS guidance criteria.
Immediate Coalition Partners: Partner directly with MPN patient advocacy groups and academic MPN investigators hungry for diverse, rural, and community-treated longitudinal cohorts underrepresented in academic biobanks.

← Return to Main JAK2+ Myelofibrosis Briefing Hub & Agent Prompt Tester